Olverembatinib in chronic myeloid leukemia.
Drugs of today (Barcelona, Spain : 1998), cilt.58, sa.11, ss.531-538, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 58 Sayı: 11
- Basım Tarihi: 2022
- Doi Numarası: 10.1358/dot.2022.58.11.3441854
- Dergi Adı: Drugs of today (Barcelona, Spain : 1998)
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE, DIALNET
- Sayfa Sayıları: ss.531-538
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
The introduction of tyrosine kinase inhibitors (TKIs) rep resents a new era in the management of chronic myeloid leukemia (CML). Despite their long clinical suc-cess, point mutations emerging before or during TKI treatment remain an obstacle for several cases. T315I is one of these point mutations in the tyrosine kinase domain of BCR::ABL1. It is a major cause of resistance against first-and second-generation TKIs and there-fore lowers survival rates of a small group of patients. Olverembatinib (HQP-1351, formerly GZD-824) is a novel, orally active TKI, which acts through targeting the ATP-binding site of the BCR::ABL1 tyrosine kinase. In recent studies, olverembatinib appears to be an eff-ective and safe treatment option for CML patients har-boring T315I mutation. This article mainly focuses on the efficacy and safety data of olverembatinib along with other clinically available and potentially active drugs against T315I-mutated CML.